MedTrace Logo

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2021-03-02

Study results available
· View outcomes & findings →

Summary

This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD). The study plans to recruit 300 subjects in the United States and Canada in which the participating physician has decided to treat with INFLECTRA. The study will evaluate treatment patterns, adherence, disease activity, remission status, relapse status, treatment satisfaction, and healthcare resource utilization. Patient outcomes will be assessed at four time points (quarterly) for approximately 52 weeks after the decision to initiate treatment with INFLECTRA.

Conditions

  • Inflammatory Bowel Disease (IBD)
  • Crohn's Disease (CD)
  • Ulcerative Colitis (UC)

Interventions

DRUG

Inflectra

The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2020-02-07
Completion
2020-02-07

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801928 on ClinicalTrials.gov